News Headlines Article

Cancer drug maker Calithera Biosciences seeks $80 million in IPO
Silicon Valley Business Journal

Cancer drug developer Calithera Biosciences Inc. is seeking $80 million through an initial public offering, the company said in a U.S. Securities and Exchange Commission filing Monday.

The South San Francisco company, which would trade on the Nasdaq exchange as “CALA,” has long been rumored as an IPO candidate, especially since so-called crossover funds backed Calithera’s $35 million Series D round last fall.

Commands